{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T02:03:10Z","timestamp":1784253790612,"version":"3.55.0"},"reference-count":31,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Aim: To evaluate the real-world effectiveness, durability, and safety of faricimab 6 mg in eyes with treatment-refractory retinal vein occlusion (RVO)-associated macular oedema (MO) in the United Kingdom (UK). Methods: This was a retrospective, single-centre observational study of eyes with RVO that were switched to faricimab after prior treatment with previous anti-vascular endothelial growth factor (anti-VEGF) agents. Baseline demographics, treatment history, pinhole visual acuity (VA), optical coherence tomography (OCT) biomarkers, and injection intervals were recorded. Eyes were treated using a treat-and-extend regimen without a loading phase. Functional, anatomical, durability, and safety outcomes were assessed over follow-up. Results: A total of 22 eyes from 22 patients were included, with a mean (SD) age of 67.9 (11.9) years and a mean (SD) RVO duration of 201.4 (153.1) weeks. Eyes had received a mean (SD) of 20.8 (16.9) prior anti-VEGF injections. The mean (SD) follow-up was 45.7 (15.8) weeks, with a mean (SD) of 5.9 (2.3) faricimab injections. There was no significant change in pinhole VA (53.5 (18.5) vs. 55.0 (18.8) letters, p = 0.08). The central subfield thickness (CST) reduced from 407.6 (102.1) to 377.0 (186.5) \u00b5m, and the maximum central retinal thickness from 483.6 (103.1) to 442.2 (187.2) \u00b5m, although these changes were not statistically significant (p &gt; 0.05). The proportion of eyes with subretinal fluid (SRF) decreased from 18.2% to 4.5%, and intraretinal fluid (IRF) from 100% to 81.8%. Injection intervals between the first and second faricimab injections increased significantly from 4.9 (1.4) to 7.7 (3.4) weeks (final injection interval, p = 0.004). Six eyes (27.3%) discontinued faricimab, with three (13.6%) requiring an intravitreal dexamethasone implant following a suboptimal response. One eye (4.5%) developed transient intraocular pressure elevation; no cases of intraocular inflammation or endophthalmitis were observed. Conclusions: In this heavily pre-treated, chronic RVO cohort, switching to faricimab without a loading phase resulted in stable visual acuity, modest but non-significant anatomical improvements, and a significant extension in treatment intervals. These findings suggest that faricimab may provide durability benefits and disease stabilisation in treatment-refractory RVO, although functional gains may be limited in chronic disease. Further prospective studies are required to define optimal switching strategies.<\/jats:p>","DOI":"10.3390\/life16071183","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:55:59Z","timestamp":1784249759000},"page":"1183","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Early Real-World Experience of Switching to Faricimab for Macular Oedema Secondary to Vein Occlusion"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-1583-6428","authenticated-orcid":false,"given":"Muiz","family":"Musadiq","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Royal Stoke University Hospital, Stoke-on-Trent ST4 6QG, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8769-0582","authenticated-orcid":false,"given":"Emer","family":"Chang","sequence":"additional","affiliation":[{"name":"Academic Unit of Ophthalmology, Department of Inflammation and Ageing, School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham, Birmingham B15 2TT, UK"},{"name":"Birmingham and Midland Eye Centre, Sandwell and West Birmingham NHS Trust, Birmingham B18 7QH, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3319-3796","authenticated-orcid":false,"given":"Abison","family":"Logeswaran","sequence":"additional","affiliation":[{"name":"Moorfields Eye Hospital, London EC1V 2PD, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8571-2503","authenticated-orcid":false,"given":"Matthew","family":"Azzopardi","sequence":"additional","affiliation":[{"name":"Moorfields Eye Hospital, London EC1V 2PD, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Musadiq","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Royal Stoke University Hospital, Stoke-on-Trent ST4 6QG, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8798-066X","authenticated-orcid":false,"given":"Yu Jeat","family":"Chong","sequence":"additional","affiliation":[{"name":"Academic Unit of Ophthalmology, Department of Inflammation and Ageing, School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham, Birmingham B15 2TT, UK"},{"name":"Birmingham and Midland Eye Centre, Sandwell and West Birmingham NHS Trust, Birmingham B18 7QH, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/S0140-6736(20)31559-2","article-title":"Retinal Vascular Occlusions","volume":"396","author":"Scott","year":"2020","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/s41433-022-02007-4","article-title":"Retinal Vein Occlusion (RVO) Guideline: Executive Summary","volume":"36","author":"Nicholson","year":"2022","journal-title":"Eye"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/APO.0000000000000598","article-title":"Update on Retinal Vein Occlusion","volume":"12","author":"Romano","year":"2023","journal-title":"Asia Pac. J. Ophthalmol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1016\/j.ophtha.2010.01.060","article-title":"Natural History of Central Retinal Vein Occlusion: An Evidence-Based Systematic Review","volume":"117","author":"McIntosh","year":"2010","journal-title":"Ophthalmology"},{"key":"ref_5","first-page":"CD007325","article-title":"Anti-Vascular Endothelial Growth Factor for Macular Oedema Secondary to Central Retinal Vein Occlusion","volume":"2014","author":"Braithwaite","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.survophthal.2025.05.008","article-title":"Effectiveness and Safety of Anti-Vascular Endothelial Growth Factor Therapies for Macular Edema in Retinal Vein Occlusion: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials","volume":"70","author":"Chen","year":"2025","journal-title":"Surv. Ophthalmol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e001086","DOI":"10.1136\/bmjophth-2022-001086","article-title":"Antivascular Endothelial Growth Factor for Macular Oedema Secondary to Retinal Vein Occlusion: A Systematic Review and Meta-Analysis","volume":"7","author":"Xu","year":"2022","journal-title":"BMJ Open Ophthalmol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1016\/j.ophtha.2012.05.017","article-title":"BRAVO and CRUISE Study Groups. Improved Vision-Related Function after Ranibizumab for Macular Edema after Retinal Vein Occlusion: Results from the BRAVO and CRUISE Trials","volume":"119","author":"Varma","year":"2012","journal-title":"Ophthalmology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.ophtha.2015.09.035","article-title":"Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: 52-Week Results of the VIBRANT Study","volume":"123","author":"Clark","year":"2016","journal-title":"Ophthalmology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","article-title":"Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-Related Macular Degeneration","volume":"119","author":"Heier","year":"2012","journal-title":"Ophthalmology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41433-025-04089-2","article-title":"Treatment Patterns and Long-Term Outcomes in Anti-VEGF-Treated Macular Oedema Secondary to Retinal Vein Occlusion: A Retrospective Observational Study","volume":"40","author":"Dinah","year":"2026","journal-title":"Eye"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1136\/bjophthalmol-2020-317337","article-title":"Visual Acuity Outcomes and Anti-VEGF Therapy Intensity in Macular Oedema Due to Retinal Vein Occlusion: A Real-World Analysis of 15 613 Patient Eyes","volume":"105","author":"Ciulla","year":"2021","journal-title":"Br. J. Ophthalmol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1001\/jamaophthalmol.2021.5619","article-title":"Visual Outcomes Associated with Patterns of Macular Edema Resolution in Central Retinal Vein Occlusion Treated with Anti-Vascular Endothelial Growth Factor Therapy: A Post Hoc Analysis of the Lucentis, Eylea, Avastin in Vein Occlusion (LEAVO) Trial","volume":"140","author":"Gurudas","year":"2022","journal-title":"JAMA Ophthalmol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.15252\/emmm.201505889","article-title":"Targeting Key Angiogenic Pathways with a Bispecific CrossMAb Optimized for Neovascular Eye Diseases","volume":"8","author":"Regula","year":"2016","journal-title":"EMBO Mol. Med."},{"key":"ref_15","first-page":"e164","article-title":"Increased Intravitreal Angiopoietin-2 Levels in Patients with Retinal Vein Occlusion","volume":"92","author":"Tuuminen","year":"2014","journal-title":"Acta Ophthalmol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/s41433-020-01377-x","article-title":"Angiopoietin\/Tie2 Signalling and Its Role in Retinal and Choroidal Vascular Diseases: A Review of Preclinical Data","volume":"35","author":"Joussen","year":"2021","journal-title":"Eye"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.ophtha.2024.01.029","article-title":"Efficacy and Safety of Faricimab for Macular Edema Due to Retinal Vein Occlusion: 24-Week Results from the BALATON and COMINO Trials","volume":"131","author":"Tadayoni","year":"2024","journal-title":"Ophthalmology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.oret.2025.03.005","article-title":"Faricimab Treat-and-Extend Dosing for Macular Edema Due to Retinal Vein Occlusion: 72-Week Results from the BALATON and COMINO Trials","volume":"9","author":"Danzig","year":"2025","journal-title":"Ophthalmol. Retina"},{"key":"ref_19","unstructured":"National Institute for Health and Care Excellence (2024). Faricimab for Treating Visual Impairment Caused by Macular Oedema After Retinal Vein Occlusion, NICE."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1136\/bjophthalmol-2019-315192","article-title":"Subthreshold Laser Therapy for Macular Oedema from Branch Retinal Vein Occlusion: Focused Review","volume":"104","author":"Eng","year":"2020","journal-title":"Br. J. Ophthalmol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.survophthal.2025.08.016","article-title":"Predicting Treatment Response in Retinal Vein Occlusions Using Baseline Optical Coherence Tomography Biomarkers: A Systematic Review","volume":"71","author":"Hatamnejad","year":"2026","journal-title":"Surv. Ophthalmol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s10792-025-03687-z","article-title":"Exploring the Role of Oxidative Stress in Retinal Vein Occlusion: An Updated and Comprehensive Review on the Pathophysiology and Treatment Perspectives","volume":"45","author":"Zhang","year":"2025","journal-title":"Int. Ophthalmol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"100302","DOI":"10.1016\/j.xops.2023.100302","article-title":"BALATON and COMINO: Phase III Randomized Clinical Trials of Faricimab for Retinal Vein Occlusion: Study Design and Rationale","volume":"3","author":"Hattenbach","year":"2023","journal-title":"Ophthalmol. Sci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s40942-025-00703-3","article-title":"Short-Term Real-World Effectiveness of Faricimab on Macular Edema Due to Retinal Vein Occlusion","volume":"11","author":"Hirakata","year":"2025","journal-title":"Int. J. Retin. Vitr."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Hafner, M., Herold, T.R., Kufner, A., Asani, B., Ansch\u00fctz, A., Eckardt, F., Priglinger, S.G., and Schiefelbein, J. (2025). Switching to Faricimab in Therapy-Resistant Macular Edema Due to Retinal Vein Occlusion: Initial Real-World Efficacy Outcomes. J. Clin. Med., 14.","DOI":"10.3390\/jcm14072454"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Hafner, M., Herold, T.R., Kufner, A., Eckardt, F., Asani, B., Priglinger, S.G., and Schiefelbein, J. (2025). Extended Real-World Efficacy of Faricimab in Therapy-Resistant Macular Edema Due to Retinal Vein Occlusion: 9-Month Follow-Up Results. J. Clin. Med., 14.","DOI":"10.3390\/jcm14207197"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.preteyeres.2015.06.002","article-title":"Molecular Pathogenesis of Retinal and Choroidal Vascular Diseases","volume":"49","author":"Campochiaro","year":"2015","journal-title":"Prog. Retin. Eye Res."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Munk, M.R., Ceklic, L., Stillenmunkes, R., Chaudhary, V., Waheed, N., Chhablani, J., de Smet, M.D., and Tillmann, A. (2024). Integrated Assessment of OCT, Multimodal Imaging, and Cytokine Markers for Predicting Treatment Responses in Retinal Vein Occlusion Associated Macular Edema: A Comparative Review of Anti-VEGF and Steroid Therapies. Diagnostics, 14.","DOI":"10.3390\/diagnostics14171983"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"969","DOI":"10.2147\/OPTH.S203212","article-title":"Vitrectomy for Macular Edema Due to Retinal Vein Occlusion","volume":"13","author":"Kumagai","year":"2019","journal-title":"Clin. Ophthalmol."},{"key":"ref_30","first-page":"24741264251358623","article-title":"Intraocular Inflammation Following Intravitreal Faricimab: Insights from Five Bilateral Cases","volume":"9","author":"Dhillon","year":"2025","journal-title":"J. Vitreoretin. Dis."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ophtha.2010.04.019","article-title":"Natural History of Visual Outcome in Central Retinal Vein Occlusion","volume":"118","author":"Hayreh","year":"2011","journal-title":"Ophthalmology"}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/16\/7\/1183\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T01:07:19Z","timestamp":1784250439000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/16\/7\/1183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":31,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["life16071183"],"URL":"https:\/\/doi.org\/10.3390\/life16071183","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,16]]}}}